Advertise on podcast: Clinician's Roundtable

Host: Maria Berrocal Guest: Dimitra Skondra, MD Could metformin reduce risk of wet AMD development? Maria Berrocal, MD, speaks with Dimitra Skondra, MD, PhD, about a study published in Ophthalmology Retina finding that metformin exposure was associated with up to 30% lower odds of new-onset wet AMD. They discuss what the findings mean for patients with and without diabetes, where the protective effect appears to break down, and what a prospective trial could tell us next.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: John A. Scolaro, MD MA For anticoagulated patients with orthopedic or trauma fractures, delaying surgery to reduce bleeding risk may carry its own consequences. Join Dr. Charles Turck and Dr. John Scolaro as they explore how factors like surgical approaches, anticoagulation indications, comorbidities, transfusion-related risks, and physiologic reserve inform reversal decisions and discuss why multidisciplinary communication and timely intervention are critical throughout perioperative care and rehabilitation. Dr. Scolaro is an Associate Professor, Residency Program Director, and Chief of Orthopedic Trauma in the Department of Orthopedic Surgery at the University of California, Irvine.

Guest: Darilyn Moyer, MD, MACP, FRCP, FIDSA, FAMWA, FEFIM With vaccination rates at historic lows and trust in public health institutions declining, primary care clinicians remain one of the most trusted sources of guidance for patients. Hear from Dr. Darilyn Moyer, Executive Vice President and Chief Executive Officer of the American College of Physicians, as she shares strategies for navigating difficult conversations about vaccines and preventive care.

Host: Barton Lynn Blackorby, MD Guest: Kyle Davis Kovacs, MD Guest: Matthew Starr, MD How aggressively should you manage a vitreous hemorrhage after a PVD when you can't see the retina underneath it? Barton Blackorby, MD, moderates a discussion with Matt Starr, MD, and Kyle Kovacs, MD, about a study published in Ophthalmology by Hasbolat et al examining 366 patients with PVD-related vitreous hemorrhage initially managed with observation. The panel discusses how exam technique and B-scan reliance may affect detachment detection rates, debates follow-up intervals given that most retinal detachments in the study occurred within the first 3 weeks, and shares their own thresholds for moving to early vitrectomy versus continued observation, including how they counsel patients eager for faster visual recovery.

Host: Maria Berrocal Guest: Sumit Sharma, MD What happens when vitreous hemorrhage (VH) secondary to non-tractional PDR doesn't clear on its own? And does preoperative anti-VEGF actually change surgical outcomes? Maria Berrocal, MD, speaks with Sumit Sharma, MD, about a retrospective case series of 360 patients who underwent vitrectomy for non-clearing VH without tractional elements, examining whether preoperative anti-VEGF injection affects the risk of postoperative rebleeding, when to consider repeat vitrectomy, and how both physicians approach these cases in their own practices.

Host: Shelina Ramnarine, PhD Guest: David A. Johnson, MD, FACG, FACP Noninvasive colorectal cancer screening is only effective when abnormal results lead to timely, high-quality colonoscopy, but recent data shows significant gaps in follow-up. Join Dr. Shelina Ramnarine and Dr. David Johnson, Chief of Gastroenterology at Eastern Virginia Medical School at Old Dominion University, as they explore how primary acre clinicians can set expectations with patients, address barriers to follow-up, and strengthen workflows and care coordination to close the loop.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mallik Greene, PhD Guest: Jordan Karlitz, MD A study published in the Journal of the National Comprehensive Cancer Network examined follow-up colonoscopy rates after positive stool-based colorectal cancer screening tests, finding notably higher and faster completion rates with multi-target stool DNA testing compared to fecal immunochemical testing. These findings highlight the critical role of patient navigation in closing follow-up gaps and reducing disparities across racial and ethnic groups. Joining Dr. Peter Buch to discuss their research and its implications for everyday practice are Dr. Mallik Greene and Dr. Jordan Karlitz. Dr. Greene is a health economics and outcome research expert at Abbott Cancer Diagnostics, and Dr. Karlitz is a volunteer gastroenterology professor at the University of Colorado School of Medicine and a Senior Medical Officer at Abbott Cancer Diagnostics. Read the JNCCN study: Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and Ethnicity

Host: Brian P. McDonough, MD, FAAFP Guest: David A. Lieberman, MD Long-term effectiveness of colorectal cancer (CRC) screening depends on more than the performance of an individual test; it requires sustained adherence to recommended screening intervals and timely follow-up after abnormal results. But real-world data shows that many patients fall off track over time. Learn more about how we can improve adherence, reduce disparities, and strengthen continuity across the screening pathway as Dr. Brian McDonough sits down with Dr. David Lieberman, Professor Emeritus in the Department of Medicine and former Chief of the Division of Gastroenterology and Hepatology at Oregon Health & Science University in Portland.

Host: Shelina Ramnarine, PhD Guest: Samuel Ubanyionwu, PharmD, EMBA Accurate IV medication delivery depends on more than proper pump programming alone. It requires a comprehensive understanding of smart pump drug libraries, dose error reduction software (DERS), infusion mechanics, and system-level safety procedures. To explore how these elements work together to support IV medication accuracy, patient safety, and clinical decision-making, Dr. Shelina Ramnarine speaks with Dr. Samuel Ubanyionwu, Medication Management Informaticist in Pharmacy Services and an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine.

Guest: Sayna Norouzi, MD Because patients with IgA nephropathy (IgAN) often have few symptoms early in the disease course, communicating the importance of treatment and its impacts on long-term outcomes can be challenging. Join Dr. Sayna Norouzi as she discusses practical communication techniques for explaining prognosis, setting expectations around therapy, and partnering with patients to support informed treatment decisions and long-term kidney health. Dr. Norouzi is an Associate Professor of Medicine and Clinical Nephrologist at Loma Linda University Medical Center in California. She's also the Founder and Director of the Glomerular Diseases Clinic at Loma Linda and Director of the GlomCon Glomerular Diseases Fellowship Program.

Guest: Anjay Rastogi, MD, PhD Closer collaboration between nephrologists and pathologists is essential for optimizing the diagnosis and management of IgA nephropathy (IgAN). Hear from Dr. Anjay Rastogi as he highlights how pathology insights, clinical context, and ongoing communication can improve interpretation of kidney biopsy findings and support more informed treatment decisions. He's a Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, as well as the Director of the UCLA CORE Kidney Health Program.

Guest: Anjay Rastogi, MD, PhD Managing IgA nephropathy (IgAN) is becoming increasingly complex. In this episode, Dr. Anjay Rastogi explains why an expert opinion—not simply a second opinion—can help clinicians confirm diagnoses, optimize treatment decisions, and connect appropriate patients with specialized care and emerging therapeutic opportunities. Dr. Rastogi is a Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA. He's also the Director of the UCLA CORE Kidney Health Program.

Host: Brian P. McDonough, MD, FAAFP Guest: Doreen Addrizzo-Harris, MD The biggest challenge in diagnosing nontuberculous mycobacterial (NTM) lung disease isn't confirmation; it's thinking to look for NTM in the first place. In this conversation with Dr. Brian McDonough, Dr. Doreen Addrizzo-Harris examines the subtle clinical and radiographic features that can help identify NTM earlier, discusses best practices for obtaining diagnostic cultures, and reviews how guideline-based criteria can help distinguish active disease from colonization. Dr. Addrizzo-Harris is the Fiona and Stanley Druckenmiller Professor of Pulmonary, Critical Care, and Sleep Medicine at NYU Grossman School of Medicine, as well as the Director of the Bronchiectasis and NTM Program at NYU Langone Health.

Host: Alexandria May, PharmD, BCPS Guest: David E. Griffith, MD Even as our understanding of nontuberculous mycobacterial (NTM) lung disease advances, major gaps remain, from defining meaningful treatment success to overcoming innate drug resistance. In this conversation with Dr. Alexandria May, Dr. David Griffith shares his perspective on how recent evidence is shaping treatment decisions for these patients and explains why significant unmet needs persist. Dr. Griffith is a Professor of Medicine in the Division of Mycobacterial and Respiratory Infections within the Department of Medicine at National Jewish Health in Denver.

What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.